Changes to the Board of Directors and Executive Board
As communicated on 18 September 2025, the Board of Directors nominated Laurent Dubois, Member of the Board since 2020, as new Chairman of the Board to be elected at the Annual General Meeting 2026, following the retirement of Dr. Valentin Chapero Rueda, effective as of the Annual General Meeting 2026. All other Members of the Board of Directors are standing for re-election at the Annual General Meeting 2026.
In December 2025, the Board of Directors appointed David Hale as the new CEO, effective 4 February 2026. David Hale brings more than 25 years of international leadership experience in the medical device and pharmaceutical industries, including senior roles at General Electric and Guerbet Group.
David Hale follows Michael Reitermann, Member of the Board since 2020, and Delegate of the Board of Directors, who acted as CEO ad interim from 29 September 2025 to 3 February 2026.








